Trial site
Moscow
- 15running trials
- 21closed trials
The trials here
What the 36 trials at this site are about, from their registry records.
- Conditions
- Childhood cancers6 trials
- Chronic myeloid leukaemia5 trials
- Lung cancer4 trials
- Multiple sclerosis4 trials
- Coronary artery disease3 trials
- Familial hypercholesterolaemia3 trials
- Myeloproliferative neoplasms3 trials
- Acute myeloid leukaemia2 trials
- Melanoma2 trials
- Metastatic breast cancer2 trials
- Stroke2 trials
- Acute lymphoblastic leukaemia1 trial
- and 15 more
- Phase
- Phase 318 trials
- Phase 27 trials
- Phase 45 trials
- Phase 1/21 trial
- Status
- Completed18 trials
- Active, not recruiting14 trials
- Terminated3 trials
- Recruiting1 trial
- Lead sponsor
- Novartis Pharmaceuticals36 trials
Running trials
Active, not recruiting
Recruiting
Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients
Active, not recruiting
Active, not recruiting
Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Coronary artery disease1 recruiting
Closed trials
Recruiting
Completed
Completed
Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
Completed
Completed
Terminated
Completed
Terminated
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
Completed
Completed
Completed
Completed
Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Completed
Completed
Site data: ClinicalTrials.govUpdated 17 Nov 2026